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Abstract: When breast cancer progresses to a metastatic stage, survival rates decline rapidly and it 
is considered incurable. Thus, deciphering the critical mechanisms of metastasis is of vital 
importance to develop new treatment options. We hypothesize that studying the proteins that are 
newly synthesized during the metastatic processes of migration and invasion will greatly enhance 
our understanding of breast cancer progression. We conducted a mass spectrometry screen 
following bioorthogonal noncanonical amino acid tagging to elucidate changes in the nascent 
proteome that occur during epidermal growth factor stimulation in migrating and invading cells. 
Annexin A2 was identified in this screen and subsequent examination of breast cancer cell lines 
revealed that Annexin A2 is specifically upregulated in estrogen receptor negative (ER-) cell lines. 
Furthermore, siRNA knockdown showed that Annexin A2 expression promotes the proliferation, 
wound healing and directional migration of breast cancer cells. In patients, Annexin A2 expression 
is increased in ER- breast cancer subtypes. Additionally, high Annexin A2 expression confers a 
higher probability of distant metastasis specifically for ER- patients. This work establishes a pivotal 
role of Annexin A2 in breast cancer progression and identifies Annexin A2 as a potential therapeutic 
target for the more aggressive and harder to treat ER- subtype. 
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1. Introduction 
All cells, including tumor cells, exist not in a vacuum but in a continuous, interconnected and 
unbounded network of relationships. This includes relationships with other cells and with the 
extracellular or stromal environment in which the cells reside. In the case of tumor cells, these 
surroundings are collectively known as the tumor microenvironment (TME)[1]. Understanding how 
the TME can affect cellular behavior is of particular interest in attempts to elucidate the cellular 
mechanisms that enable a metastatic phenotype. This is because two of the cellular behaviors 
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essential to the process of metastasis (migration and invasion) rely on interactions between the tumor 
cell and its surrounding TME [2,3]. In migration, cells gain the ability to become aberrantly motile. 
This motility is given directionality via chemotaxis in which a receptor expressed by the cancer cells 
interacts with a chemoattractant ligand present within the TME [4]. Invasion, referred to as the 
defining feature of malignancy, is the ability of cancer cells to change their morphology and alter 
their surroundings in order to penetrate the basement membrane, degrade encompassing stroma and 
escape usual tissue boundaries [5]. These pivotal mechanisms of cancer disease progression can be 
modelled in vitro using cell lines and well-defined transwell migration and invasion assays [6]. 
Deciphering the steps involved in the metastatic process is of vital importance in breast cancer. 
Breast cancer begins as a disease localized to the breast tissue. Advancements in multi-modal 
treatments such as surgery and radiation, have increased the chances for cure for over 70% of patients 
[7]. However, the mortality associated with the disease of breast cancer does not arise from these 
localized breast tumors but rather, from when the cancer undergoes metastasis and spreads to distant 
sites and colonizes vital organs of the body. At present, metastatic breast cancer is considered 
incurable. Once this stage of disease is reached, treatment aims to prolong survival and control 
symptoms. For this reason, there is an urgent need to decipher the specific environmental cues and 
resultant mechanisms involved in the metastatic process. This is of particular importance in estrogen 
receptor (ER) negative breast cancer subtypes (including both the triple negative (TNBC) and HER2+ 
groupings) as these tumors have a more aggressive phenotype and higher rate of distant metastasis 
than ER positive tumors [8]. This understanding will guide the development of interventions aimed 
at preventing the metastasis and associated mortality seen in those diagnosed with ER negative breast 
cancer. 
One method to assess the effect of environmental cues is to study the resulting influence on the 
cell’s proteome [9]. There is strong evidence that proteomic analysis offers a truer physiological 
insight over transcriptomic methods. Measurements of mRNA transcript abundance alone have been 
reported to be a poor predictor of protein synthesis due to the fact it is subject to an independent 
layer of translational control that controls protein expression [10]. Transcriptomics also fails to take 
into account protein turnover and degradation as well as activation state through post-translational 
modification. Proteomic analysis of breast cancers has revealed prognostic markers [11], novel 
subtype classifications [12] and targetable protein abundance differences as cancer progresses 
through clinical stages [13]. Analysis of proteins that are newly translated and synthesized by cells 
allows for an accurate snapshot of cellular activities during a specific process or duration. In fact, the 
execution of cancer hallmarks—such as migration and invasion—which drive progression are 
ultimately achieved by dynamic alterations in protein expression and post-translational 
modifications of those proteins [14]. 
With this in mind, we have developed a model to investigate changes in the nascent proteome 
of aggressive, ER negative breast cancer cells as they undergo migration and invasion, stimulated 
through modulation of the extra-cellular environment. In this study, we utilized these in vitro 
transwell models in combination with bioorthogonal noncanonical amino acid tagging (BONCAT) to 
investigate proteomic changes in MDA-MB-231 breast cancer cells as they undergo epidermal growth 
factor (EGF) mediated migration and invasion. BONCAT is a widely used method to assess the 
primary nascent proteomic response to a specific stimulus within a specific short time period [9]. This 
method allowed us to isolate and identify newly synthesized proteins that were translated in the two 
hours following directional EGF stimulation. Metastasis is a dynamic process of changes in cellular 
expression and behaviors and thus, must be investigated via a dynamic and temporal model. 
Isolating the nascent proteome in this manner facilitates the precise examination of the cancer cell’s 
translational response to environmental cues, which trigger a metastatic phenotype. This knowledge 
may elucidate novel therapeutic strategies or treatments that prevent the metastatic spread of cancer 
cells. 
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2. Materials and Methods 
2.1. Cell Culture 
Human breast cancer cell lines (MDA-MB-231, MCF-7, ZR-75-1) were purchased from the 
ECACC culture collection (Sigma Aldrich, Wicklow, Ireland). Cell lines were routinely tested upon 
freezing and thawing for mycoplasma contamination using PCR. Cells were maintained at 37 °C, 5% 
CO2 humidified incubator in DMEM-high glucose (MDA-MB-231 & MCF-7) or RPMI (ZR-75-1) 
supplemented with 10% fetal bovine serum, 5% l-glutamine and 5% penicillin/streptomycin (all 
obtained from Sigma Aldrich). ZR-75-1 media was additionally supplemented with 5% sodium 
pyruvate (Sigma Aldrich). For 3-dimensional culture, the on-top method was used where cells were 
seeded into wells containing Growth-Factor Reduced Matrigel™ (Biosciences, Dublin, Ireland) then 
covered with DMEM supplemented with 2% Matrigel. For analysis of cell signaling, cells were 
washed with PBS before being covered with serum free medium for 4 h prior to EGF stimulation 
(Peprotech, London, UK). 
2.2. Click-iT Reaction 
Cell cultures plated in 2-D (24 h) and 3-D (6 day) on transwell membranes were starved of serum 
and methionine for 4 h. After this, serum free, methionine free DMEM supplemented with 50 ng/mL 
EGF was placed into the lower chamber. At the same time, the upper chamber media was replaced 
with serum free, methionine free DMEM supplemented with 50 μM Azido Homo Alaine (AHA) 
(Thermo Fisher, Dublin, Ireland), a methionine analogue that is incorporated into newly synthesized 
proteins. Cells were then allowed to migrate and invade for 2 h. Cells were harvested from Matrigel 
or scraped from the membrane then lysed. The Click-iT reaction and incorporation of the 
tetramethylrhodamine (TAMRA) tag was then carried out according to Click-iT TAMRA Protein 
Analysis Detection Kit protocol (Thermo Fisher) to isolate newly synthesized proteins which had 
incorporated the AHA labelling. A control replicate omitting the EGF supplementation was carried 
out for both 2-D and 3-D cultures. 
2.3. Immunoprecipitation 
Newly synthesized proteins that had incorporated the TAMRA residue were then isolated from 
total cell lysate using anti-TAMRA immunoprecipitation. Lysates were precleared with protein G 
agarose beads (Roche, via Sigma Aldrich). The supernatant was then incubated with Anti-TAMRA 
antibody (Thermo Fisher) and protein G agarose beads at 4 °C overnight. The beads were washed 
with cell lysis buffer before being boiled with SDS loading buffer for 5 min. Immunoprecipitated 
samples were resolved on a 12% SDS gel and stained with Coomassie Instant Blue (Expedeon, 
Cambridge, UK). A control containing only beads was also performed to account for non-specific 
binding and contaminant exclusion. 
2.4. Mass Spectrometry and Data Analysis 
Following SDS-PAGE, gel lanes containing protein bands stained with Coomassie were excised 
from the gel and placed in 20% glycerol for transport to Mass Spectrometry and Proteomics Facility, 
University of St Andrews, Fife. Gel chunks were subjected to trypsin digestion. Next, proteolytic 
peptide mixtures were separated by nano-LC utilizing an Eksigent two-dimensional LC NanoLC 
system (Eksigent/Applied Biosystems Sciex, MA, USA) interfaced with a QStar XL mass spectrometer 
(Applied Biosystems Sciex, MA, USA). Data sets were searched against the NCBInr 20160830 
database using MASCOT software (Matrix Science, MA, USA) under the following parameters: 
maximum one missed cleavage of trypsin digestion, carbamidomethyl (C) as a fixed modification, 
oxidation (M) as a variable modification, a peptide mass tolerance of ± 20 ppm and a fragment mass 
tolerance of ±0.05 Da. Only scores higher than the significance threshold (p < 0.05) were reported. 
Proteins identified in bead only and non-EGF supplemented controls were subtracted from the 
protein lists. Proteins were then characterized functionally based on the available literature 
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associated with their NCBI entry. Gene ontology (Molecular Function–Slim) enrichment analysis was 
carried out using the Panther overrepresentation test (Version 14.1) [15] with the Fisher’s exact test 
to calculate p-value and Benjamini–Hochberg procedure to calculate false discovery rate (FDR). FDR 
cut-off was <0.05. Protein-protein interaction networks were probed using STRING v11[16] and 
visualized using Cytoscape StringApp [17]. 
2.5. Cell Lysis, SDS PAGE and Western Blotting 
The cells were lysed in 1% NP-40 lysis buffer then quantified and denatured with SDS loading 
buffer and boiled for 5 min. Lysates were separated on 12% SDS acrylamide gels and subsequently 
transferred to nitrocellulose membrane. Membranes were blocked using 5% BSA for 1 h at room 
temperature then probed with corresponding primary antibodies at 4 °C overnight. Dilutions of 
antibodies were as follows: Annexin A2 1:1000 (Abcam, Cambridge UK), Annexin A2 1:1000 (BD 
Bioscience), B-Actin 1:1000 (Sigma), phospo-Tyr24-Annexin A2 1:250 (Santa Cruz Biotechnology, 
Heidelberg, Germany) E-Cadherin 1:1000 (Abcam). IRdye700- or IRdye800-conjugated secondary 
antibodies, were then coupled to the primary antibody for 1 h at room temperature. Protein bands were 
detected using the Odyssey Sc (LI-COR, Cambridge, UK).and quantified using Image Studio 5.2 (LI-
COR)). 
2.6. siRNA Transfection 
To reduce Annexin A2 expression, the Neon Transfection System (Thermo Fisher) was used to 
transiently transfect MDA-MB-231 cells with siRNA oligonucleotides targeting ANXA2 mRNA 
according to the protocol supplied by Neon. Two different siRNA oligonucleotides were obtained from 
Qiagen (Manchester, UK) and used at 10 nM for 72 h (Sequences reported in Table S3). MISSION® 
siRNA Universal Negative Control (Sigma Aldrich) was transfected as negative control. 
2.7. Tissue Collection 
Ethical approval was granted by the University Hospital Limerick’s Ethics Committee and was 
allocated the ethical approval numbers 22/14 and 141/12. From the resected surgical specimens, core 
biopsies from the tumor mass were extracted by the operating surgeon. Where possible, pathologically 
normal breast tissue samples were also collected. The samples were stored in Allprotect Tissue Reagent 
(Qiagen) at −80 °C until extraction. 
2.8. RNA Extraction 
RNA from breast cancer cell lines was extracted using RNeasy Plus Mini kit (Qiagen) according to 
manufacturer’s instructions. For breast tissue samples, RNA was extracted by submerging tissue into 
liquid nitrogen, grinding into a fine powder then using the RNeasy Lipid Tissue Mini Kit (Qiagen) in 
combination with Maxtract tubes (Qiagen) according to manufacturer’s instructions. RNA was 
quantified using Nanodrop (Thermo Fisher) and quality was assessed by agarose gel separation. cDNA 
was then synthesized from 1 µg or 500 ng of total RNA using a Vilo cDNA kit (Invitrogen, via 
Biosciences, Dublin, Ireland). 
2.9. RT-qPCR 
Applied Biosystems QuantStudio 7 Flex Real-Time PCR was used to measure gene expression 
using Taqman Gene Expression Assay Kits (Thermo Fisher). Seven different housekeeping genes were 
tested using Normfinder and the three most stable genes between the three cell lines were used to 
normalise gene expression across samples as previously described [18]. Relative fold change in gene 
expression was calculated using the 2−ΔΔCT method and represented relative to a control sample set to 1 
for each experiment. Data presented is from three independent experiments displayed as mean +/- SEM. 
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2.10. Cell Migration Assays 
For wound healing assays, transfected cells were seeded into cell culture wells containing ibidi 
inserts (ibidi GmbH, Gräfelfing, Germany). After 72 h incubation, the insert was carefully removed and 
cells imaged using Olympus cellSens Dimension 1.12. Cells were incubated for 24 h, after which images 
of the wound closure were taken. Six fields of view were imaged for each condition and percent wound 
closure was measured using Image J (version 1.52n). Three individual experiments were carried out to 
verify results. Data is displayed as mean across three individual experiments +/- SEM. 
For directional migration assays, the underside of 8 µm transwell membranes were coated with 
fibronectin before 6 × 105 cells in serum free DMEM media were plated onto the upper chamber. Cells 
were allowed to migrate towards a lower chamber containing 50 ng/mL EGF in serum free media for 
24 h. Cells were removed from the upper chamber of the membrane. Migrated cells were fixed and 
stained with crystal violet and imaged. To quantify the cell migration, crystal violet stain was dissolved 
10% acetic acid and intensity measured as absorbance at 595 nm in triplicate. Three individual 
experiments were carried out to verify results. 
2.11. Real-Time Proliferation Assay 
The rate of proliferation was monitored in real time using the xCELLigence RTCA DP E-plate 
system (ACEA, CA, USA). 1.5 × 104 MDA-MB-231 cells transfected either with ANXA2 siRNA or 
negative control RNA were seeded into each well. The impedance value of each well was measured by 
the xCELLigence system every 15 min for 96 h and expressed as a cell index value (CI). CI was 
normalized at 4 h post seeding. Wells were analyzed in duplicate. Three individual experiments were 
carried out to verify results. Data is displayed as mean cell index +/- SEM. 
2.12. Use of Publicly Available Gene & Protein Expression Datasets 
Protein expression data of breast cancer cell lines was provided by D P Nusinow et al. [19]. Protein 
expression was measured using quantitative mass spectrometry and is expressed as normalized, 
relative values of protein abundance. Full details of normalization is available at [20]. Gene expression 
data of breast cancer cell lines was downloaded from the Cancer Cell Line Encyclopedia (CCLE) 
(Available at: https://portals.broadinstitute.org/ccle; GEO Series GSE36139). This data set was collected 
using GPL15308 Affymetrix Human Genome U133 Plus 2.0 Array. Microarray data was evaluated 
using the robust multichip average method (RMA) and quantile normalized before being made 
available through the CCLE [21]. Breast cancer cell lines were then classified by ER expression (positive 
or negative) according to the available literature [22,23] and AnxA2 mRNA expression was compared 
between groups. Dataset GSE42568 [24] was downloaded from the GEO data repository 
(http://www.ncbi.nlm.nih.gov/geo) using the GEOR function. This data set was collected using GPL570 
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. Microarray data was evaluated 
using the GC robust multichip average (GCRMA) method and quantile normalized before being made 
available through GEO. Protein expression data using SILAC quantitative mass spectrometry of 40 
breast cancer tissue samples was obtained from Tyanova et al. (2016) [25]. Normalized protein 
expression depicted as log2 (ratio of L/H). Distant metastasis free survival (interval from surgery to date 
of metastasis diagnosis) was investigated by downloading data from http://kmplot.com, a manually 
curated database which collates gene expression and survival information from GEO, EGA and TCGA 
datasets (35 breast cancer datasets, using Affymetrix HGU133A and HGU133 Plus 2.0 microarrays) [26]. 
The median ANXA2 expression value for each cohort was chosen as the high/low cut off point. 
Graphpad Prism 8 was then used to produce Kaplan–Meier graphs and to calculate log-rank test result 
and hazard ratios. 
2.13. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 8.0.2. The Shapiro–Wilk test 
was used to assess normality of sample distribution. Differences between two groups were calculated 
using Student’s T-test (normally distributed samples) or Mann Whitney U test (non-normally 
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distributed samples). Differences between three or more groups was calculated using ANOVA and 
multiple comparisons were performed using Bonferroni Correction. Data was reported as mean +/- 
standard deviation for technical replicates or mean +/- standard error of mean for biological replicates. 
A p value of <0.05 was considered statistically significant. Within figures, asterisks denote significance 
levels as such: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
3. Results 
3.1. Isolation and Identification of Newly Synthesised Proteins Involved in Breast Cancer Cell Metastasis 
In order to develop a model to investigate breast cancer metastasis in vitro, we chose MDA-MB-
231s due to their aggressive, epithelial to mesenchymal phenotype and well-evidenced ability to 
migrate and invade in vitro. Additionally, MDA-MB-231 belong to the basal/TNBC sub-type and are 
thus estrogen receptor negative and known to express the EGF receptor [23]. To determine whether 
EGF would be an effective chemoattractant in our models of migration and invasion, a series of 
transwell migration experiments were carried out. The highest level of migration of MDA-MB-231 
cells was observed when EGF was present only in the lower chamber, as evidenced in Figure 1A; 
demonstrating that EGF elicits a specific increase in directional migration. Our own observations are 
in accordance with those published in similar studies [27–30] and gives evidence to the selection of 
EGF as a trigger for the processes of migration and invasion in MDA-MB-23 cells. 
Having determined 50 ng/mL EGF to be an appropriate chemoattractant for our breast cancer 
cell line, it was selected as the stimulus in transwell migration and invasion assays in our model. The 
workflow of this model is summarized in Figure 1B. To identify the newly synthesized proteins while 
breast cancer cells undergo migration and invasion, MDA-MB-231 breast cancer cells were grown in 
2-D and 3-D culture as described in Materials and Methods. Cell cultures were serum and methionine 
starved then stimulated with EGF and supplied with AHA. After stimulation, a fluorescent TAMRA-
alkyne was added which binds to the azide moiety of the AHA-tagged newly synthesized proteins. 
This allowed for isolation of the newly synthesized proteins using anti-TAMRA in an 
immunoprecipitation reaction, with the resultant product being proteins newly synthesized 
following stimulation to migrate and invade towards an EGF chemoattractant. Proteins in these 
samples were then identified using mass spectrometry analysis. To specifically identify proteins that 
were newly translated during EGF stimulation, a control experiment without the addition of EGF 
was conducted for both the 2-D and 3-D models. Proteins identified in the EGF omitted controls were 
then subtracted from their respective EGF stimulated protein lists. 
We identified a total of 95 newly synthesized proteins potentially involved in the migration and 
invasion of MDA-MB-231 breast cancer cells towards EGF (Table S1). Characterization of the protein 
list according to NCBI Protein [31] database entries found that the list spans a wide array of functions 
within the cell, with the highest proportions being: protein modification (e.g., kinases, phosphatases, 
proteases; 20%), structural (19%), and calcium binding (19%) as summarized in Figure 1C. We then 
carried out molecular function enrichment analysis using the PANTHER overrepresentation test 
which revealed the most significantly overrepresented category was that of proteins involved in 
calcium ion binding (GO:0045296, expected:0.97, input: 9, fold enrichment: 9.31, p-value: 7.56E-07 
false discovery rate: 3.82E-04, Figure 1D). This functional characterization showed that proteins 
newly synthesized in the processes of cell migration and invasion encompass a wide variety of 
functions and numerous essential processes in cell signaling and behavior, many of which are 
implicated in cancer progression.  
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Figure 1. Isolation, identification, and functional characterization of newly synthesized proteins in 
MDA-MB-231 migration and invasion. (A) MDA-MB-231 cells were plated in the upper chamber of 
transwell plates and media was supplemented (+/- EGF) according to diagram. Cell migration after 4 
h was measured by crystal violet (CV) staining of cells which moved through the well and adhered 
to the underside of the membrane. Non-migrated cells were removed prior to staining. Membranes 
were then imaged using inverted microscope and migration of cells was quantified by dissolving of 
CV stain and measuring absorbance at 595 nm. Data displayed as mean ± SEM, of 3 independent 
experiments, CV absorbance normalized to average value for well 1. Statistical analysis by one way 
ANOVA, p = < 0.0001. (B) Flow chart of model set-up, isolation of newly synthesized proteins, and 
mass spectrographic analysis carried out in this study. (C) Characterization of identified newly 
synthesized proteins according to the NCBI database entries of each protein and displayed as pie 
chart. (D) Molecular function enrichment analysis was carried out using the PANTHER 
overrepresentation test. The numbers of proteins annotated with each molecular function was plotted 
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as a bar chart with the color scale representing the significance of the enrichment of molecular 
function within the list. 
3.2. Identification and Verification of Annexin A2 as A Newly Synthesized Protein in EGF Stimulated 
Migration and Invasion 
Of the total 95 proteins identified as newly synthesized, 41 proteins were identified in the 2-
dimensional culture migration experiment only, and 40 unique proteins were identified in the 3-
dimensional culture invasion experiment only. When displayed in the Venn diagram in Figure 2A, 
14 proteins were found to be common to both lists, meaning that they had been identified in both the 
2-D migration and 3-D invasion models. Protein-protein interaction analysis of these 14 proteins 
using STRING [16] revealed an extensively linked network within the group, (with the exception of 
NCCRP1) as seen in Figure 2B. To identify key proteins within the identified network, each node was 
assessed for its degree of centrality, edge connectivity and whether it has been previously reported 
as important in breast cancer metastasis. Annexin A2, having satisfied these criteria and was chosen 
as a candidate protein to investigate how perturbing this elucidated network would affect breast 
cancer cell migration and invasion. Annexin A2 was also chosen as it was identified in both 
experiments, was relatively highly scored and due to its molecular function as a calcium ion binding 
protein [32], a gene ontology term found to be most significantly enriched (FDR = 3.82E-04) following 
analysis of the total protein list. Annexin A2 is a member of the 12 protein annexin family, a group of 
proteins which have the ability to bind negatively charged membrane phospholipids in a calcium 
dependent manner [33,34]. In addition to the interactions illustrated in Figure 2B, Annexin A2 has 
proven links with a number of other identified proteins such as beta- actin [35]and tubulin [36]. Thus, 
it is highly probable that Annexin A2 is playing a central role in influencing this network, for example 
through its roles in actin polymerization [37] and cytoskeletal rearrangement [38,39]. In addition, due 
to the integral role and embryonic lethality of essential cytoskeletal proteins like beta actin [40], we 
believe there is more potential therapeutic value in investigating proteins that have a more 
regulatory, non-essential role, such as Annexin A2 [41]. In addition, Annexin A2 has a known clinical 
association with cancer [42] and has a role downstream of growth factor signaling pathways such as 
the IGF-IR [43] and the EGFR [44,45] pathways. This association was first established in 
hepatocellular carcinoma in 1990 [46] but to date, it has been found to be commonly overexpressed 
in multiple cancer types such as colorectal, breast, lung and pancreatic [42]. The amino acid sequence 
of Annexin A2 with the matched peptide sequences is shown in Figure S1 (Score: 169, Monoisotopic 
mass (Mr): 38808, Calculated pI: 7.57, Matches: 5, Sequences: 4, Coverage: 12%). The reported mass 
agrees with Annexin A2′s predicted molecular weight of 38 kDa. A representative MS/MS spectrum 
of one Annexin A2 peptide is also shown. Apart from Annexin A2 several other proteins of potential 
future interest were identified (Figure 2A,B). Intriguingly, a number of metabolism associated 
proteins, including GAPDH, LDHA, and GSTP1 were identified. Altered metabolism is a 
fundamental hallmark of cancer [47] and it has even been suggested that specific deregulations in the 
metabolism of metastasizing cells could be a specific therapeutic target [48]. 
Following identification of Annexin A2, we proceeded to validate it as a newly synthesized 
protein by replicating the initial migration experiment. This was done by performing a TAMRA 
immunoprecipitation (IP) of the Click-iT reaction lysate to isolate proteins that had incorporated the 
TAMRA tag then western blot analysis to show successful Annexin A2 pulldown (Figure 2C). Pull 
down of Annexin A2 is clearly increased in the AHA+ lysate sample (Panel (ii) lane 2) in comparison 
to the beads only (no antibody) control (Panel (ii), lane 1) and AHA- (non-TAMRA labeled) lysate 
control (Panel (ii), lane 3).This pulldown validates our approach and verifies our identification of 
Annexin A2 as a newly synthesized protein via mass spectrometry analysis. 
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Figure 2. Annexin A2 is newly synthesized during the EGF stimulated migration and invasion of 
MDA-MB-231 cells. (A) 95 proteins in total were identified following mass spectrometry analysis and 
MASCOT peptide identification. Of these, 41 were found in the migration experiment only, 40 were 
found in the invasion experiment only and 14 were found to be common to both, listed here. (B) 
Protein-protein interactions between the 14 proteins found to be common to both the migration and 
invasion lists were assessed with String (http://string-db.org) [16] and visualized using the StringApp 
in Cytoscape set at 0.2 confidence level [17]. Edge line thickness denotes the confidence of association 
between protein nodes. (C) (i) Input: Western blot analysis of Click-It reaction lysate shows successful 
incorporation of the TAMRA tag into newly synthesized proteins when AHA was added. (Lane 1: 
Cell lysate of EGF migrating cells without AHA, Lane 2: Cell lysate of EGF migrating cells with AHA). 
(ii) Immunoprecipitation: Consequent TAMRA immunoprecipitation assay showed Annexin A2 
pulldown following EGF induced cell migration as measured by SDS-PAGE and western blotting 
with anti-Annexin A2 antibody. (Lane 1: Beads only control, Lane 2: AHA+ lysate from lane 2 of (i), 
Lane 3 AHA- lysate from lane 1 of (i)). 
3.3. Annexin A2 Expression is Increased in Estrogen Receptor Negative Breast Cancer Cells 
Following identification and verification of Annexin A2 as a protein newly synthesized in EGF 
mediated MDA-MB-231 cell migration and invasion, we next examined its expression profile across 
a number of breast cancer cell lines. Western blotting analysis of cell protein content shows an 
increased expression of Annexin A2 in the estrogen receptor negative (ER-), basal/TNBC cell line 
MDA-MB-231 when compared to the estrogen receptor positive (ER+), luminal cell lines MCF-7 and 
ZR-75-1 (both ER+/PR+) (Figure 3A). Expression of Annexin A2 appears to inversely correlate with 
expression of E-Cadherin, the loss of which is a known marker of epithelial to mesenchymal 
transition. To further support these findings, we analyzed data from D. P. Nusinow et al. (2020) [19] 
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to generate a protein expression heatmap (Figure 3B) showing how the expression of Annexin A2, 
EGFR, and E-Cadherin vary across a larger sample of cell lines, according to breast cancer subtype 
classification. From this it is evident that there is an increase in both Annexin A2 and EGFR expression 
in the ER- (HER2 and TNBC) cell lines when compared to ER+ cell lines (further depicted in Figure 
S2). This supports and is in agreement with our conclusions drawn from our western blot data (Figure 
3A). Interestingly, we do not see an association between the loss of E-Cadherin and elevated Annexin 
A2 when we query this larger cohort of cell lines, thus the trend observed in Figure 3A may be 
attributed to individual characteristics of the three cell lines tested. When we consider the potential 
relationship between Annexin A2 and EGFR expression, our analysis shows that in ER- cell lines, 
there is a strong positive and significant correlation between the expression of these two proteins 
(Pearson’s correlation, r = 0.6026, p = 0.0023). Importantly, and in support of our hypothesis, we do 
not see this significant correlation in ER+ cell lines (r = 0.5952, p = 0.1196). 
Next, we examined Annexin A2 mRNA expression using RT-qPCR in breast cancer cell lines, 
under normal, serum starved and EGF stimulated conditions. Again, we observed Annexin A2 
expression to be increased in ER- cells in comparison to ER+ cell lines under all culture conditions 
(Figure 3 (C)). In particular, we found that following 4 h of 50 ng/mL EGF stimulation ANXA2 is even 
more highly expressed in MDA-MB-231s when compared to the other ER+ cell lines. This suggests 
that the increased expression of ANXA2 in response to EGF is specific to the ER-, EGFR expressing 
MDA-MB-231 cell line. We then utilized the available data within the Cancer Cell Line Encyclopedia 
(CCLE) [21] to further probe the relationship between ER status and AnxA2 expression. The CCLE is 
a large, publicly available data repository which compiles gene expression, chromosomal copy 
number and sequencing data from 947 human cancer cell lines, spanning 36 tumor types [21]. Breast 
cancer cell lines with ANXA2 expression data available (n = 49) were first categorized according to 
positive or negative ER status according to previously published molecular characterization studies 
[22,23]. This stratification revealed 18 of the available cell lines to be ER+ and 31 to be ER-. Comparing 
levels of ANXA2 mRNA expression between ER+ and ER- cell lines, as measured by Affymetrix U133 
plus 2.0 arrays, showed ER- lines exhibit significantly higher expression of ANXA2 (p = 0.0008) as 
shown in Figure 3D. The cell lines analyzed and their respective ANXA2 expression values are 
outlined in Figure S2. These results show that expression of Annexin A2 in breast cancer is strongly 
influenced by estrogen receptor status and that its overexpression in breast cancer may be restricted 
to the ER- subtype. ER- negative breast cancers include both TNBC and HER-2 over expressing 
subtypes, both of which are more aggressive cancers with a poorer prognosis [49]. 
As the synthesis of Annexin A2 identified in our initial experiment was triggered by stimulation 
with EGF, we investigated the effect of EGF on the regulation of Annexin A2 (Figure 3E). To control 
our experiment, we examined the p-Akt response, which was used as a read-out of our serum 
starvation and EGF stimulation. We found that stimulation of MDA-MB-231 cells with EGF resulted 
in an increase in phosphorylation of Annexin A2 on Tyrosine 24 (Tyr24) which reached a peak 
phosphorylation at 30 min, before decreasing towards, initial, pre-stimulation levels over 120 min 
(Figure 3E). This post-translational modification allows Annexin A2 to bind to S100A10 (also known 
as p11) to form the AnxA2/p11 heterotetramer which then is translocated to the extracellular cell 
surface [50,51]. This modulation is of particular relevance in cancer phenotype as once on the cell 
surface, AnxA2/p11 promotes the conversion of plasminogen to active plasmin, a protease which 
plays a role in extracellular matrix degradation and activation of matrix metalloproteases, critical 
steps in cancer cell metastasis [34,52]. In fact, Tyr24 phosphorylation has been shown to be critical for 
the invasive potential of multi-drug resistant breast cancer cells [53] and is proposed to modulate 
epithelial to mesenchymal transition in a number of cancer types, including pancreatic [54], cervical 
[55], colon [56]and lung [57]. 
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Figure 3. Annexin A2 expression is increased in ER negative breast cancer cells and undergoes 
transient phosphorylation following EGF stimulation. (A) Comparison of Annexin A2 expression in 
three breast cancer cell lines: MDA-MB-23, MCF-7 and ZR-75-1 as measured by SDS-PAGE and 
western blot. Protein expression was quantified by densitometric signal analysis on Image Studio 
software (LI-COR). Annexin A2 signal was normalized to beta-actin signal, then expressed in 
comparison to MCF-7 expression as 1. Data shown is mean +/- SEM for 3 individual experiments, 
measured by ANOVA with Bonferroni, p = 0.0034. (B) (i) Heatmap of Annexin A2, EGFR and E-
Cadherin protein expression data for breast cancer cell lines from Nusinow, D. P. et al. (2020), 
stratified according to breast cancer subtype. Protein expression represented as normalized relative 
protein expression, as measured by quantitative proteomics. (ii) Scatterplots of the same data 
indicating the relationship between Annexin A2 and EGFR protein expression. A significant and 
strong positive correlation between Annexin A2 and EGFR expression is seen for ER- cell lines 
(Pearson’s correlation, r = 0.6026, p = 0.0023) (C) Gene expression of ANXA2 in three breast cancer cell 
lines: MDA-MB-231, MCF-7 and ZR-75-1. Expression was calculated using delta CT method and 
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displayed as fold change (corrected RQ) in comparison to MCF-7 expression for each condition. (i.e., 
MCF-7 expression normalized to 1) differences between cell lines analyzed by ANOVA with 
Bonferroni. (D) Publicly available Affymetrix gene expression data for human breast cancer cell lines 
was obtained from the CCLE. Cell lines were categorized according to ER expression status and 
difference in ANXA2 expression between the 2 groups was measured using Mann–Whitney U test, p 
= 0.0008 (E) Western blot showing the effect of EGF stimulation on AnxA2 expression and 
phosphorylation in MDA-MB-231 cells. After 4 h of serum starvation, cells were treated with 50 
ng/mL EGF. Representative blot and corresponding time course graph showing the increase in AnxA2 
phosphorylation at Tyr24 followed by decrease after 30 min. Densitometry signal normalized as 
phosho-AnxA2/total AnxA2 and phospho-Akt/total beta-actin. Data points displayed as mean of 3 
individual experiments ±SEM. 
3.4. Annexin A2 is Required for Cell Proliferation, Wound Healing and EGF Directed Cell Migration of 
ER Negative Breast Cancer Cells 
Following evidence of Annexin A2′s involvement in the migration and invasion in our ER 
negative cell model, we next investigated its influence on the cancer phenotype with a series of 
functional assays. AnxA2 expression was suppressed in MDA-MB-231 cells using siRNA specific to 
AnxA2 mRNA transcript (Table S2). Figure 4A shows a representative blot of knockdown efficiency, 
showing reduced level of Annexin A2 protein in cells 72 h following transfection. Firstly, using a real 
time cell analysis platform (xCELLigence) the effect on the growth and proliferation of MDA-MB-231 
cells was monitored by measuring cell index every 15 min over the course of 96 h. As shown in Figure 
4B, the depletion of AnxA2 significantly reduced the proliferation of MDA-MB-231 cells when 
compared to control cells. Next, the effect of AnxA2 knockdown on cell migration was then assessed 
using two independent assays. We first used wound healing assays which revealed knockdown cells 
to have a significantly decreased ability to close the wound after 24 h (Figure 4C). This was followed 
by transwell chamber experiments, which specifically tested the effect on the directional migration 
and the response to an EGF chemoattractant. In this assay, MDA-MB-231 cells were plated in serum-
free media on the upper chamber of the transwell and allowed to migrate towards the bottom 
chamber, containing serum free media supplemented with 50 ng/mL EGF. We found that ANXA2 
knockdown cells were significantly reduced in their ability to migrate towards an EGF gradient 
(Figure 4D). These results are consistent with previous reports of Annexin A2 being a positive 
regulator of wound healing in MDA-MB-231 cells [44,58]. However, they also point towards the role 
of Annexin A2 in promoting specific EGF directed migration. In addition, we have shown that 
Annexin A2 knockdown inhibits the proliferative ability of the ER- MDA-MB-231 cells. These 
functional results were confirmed by replication of each assay using another clone targeting ANXA2 
(Figure S4). Taken together, this data strongly supports the hypothesis that Annexin A2 promotes 
cell proliferation, wound healing and cell migration, all critical processes which support the 
malignant phenotype of ER- breast cancer cells in vitro. 
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Figure 4. siRNA mediated knockdown of AnxA2 inhibits the proliferation and migration of MDA-
MB-231 cells. (A) MDA-MB-231 cells were transfected with a small interference oligonucleotide 
against ANXA2 [10 nM] for 72 h, using the Neon Transfection system. Representative blot showing 
the efficiency of ANXA2 knockdown (KD) after 72 h and densitometry analysis of Annexin A2 protein 
bands normalized against beta-actin loading control and expressed as a percentage of AnxA2 level in 
negative control, measured using Image Studio software. Data displayed as mean +/- SEM for three 
individual experiments. (B) Reduction of Annexin A2 expression in MDA-MB-231 cells significantly 
inhibits cell proliferation as measured by real time change in cell impedance. KD and negative control 
cells were seeded in duplicate into E-plate wells and the rate of proliferation was measured in real-
time using the xCELLigence system. Proliferation of KD cells (green) was compared to the 
proliferation of negative control wells (red) over the course of 96 h. Data displayed as mean cell index 
+/- SEM for three individual experiments. (C) Reduction of Annexin A2 expression in MDA-MB-231 
cells significantly inhibits cell migration as measured by wound healing assay. Knockdown and 
negative control cells were plated into dishes containing ibidi Culture Inserts. After 72 h, the inserts 
were removed to generate a cell free wound. The green zone indicates the wound size as measured at 
0 h and 24 h post-removal of insert. Data displayed as percent wound closure for 3 individual 
experiments (6 fields of view each) +/- SEM, p = 0.0002. (D) Reduction of Annexin A2 expression 
significantly inhibits EGF directed cell migration as measured with transwell migration chambers. 
Cells were plated onto the upper chamber of transwell membrane and allowed to migrate towards 50 
ng/mL EGF chemoattractant for 24 h. Cells were removed from the upper chamber, leaving only those 
that had migrated to the lower chamber. Migrated cells were stained with crystal violet and imaged 
using an inverted light microscope. Crystal violet stain was dissolved, and intensity measured as 
absorbance at 595 nm in triplicate. Data displayed as mean absorbance values for 3 individual 
experiments +/- SEM, p < 0.0001. 
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3.5. Gene Expression Analysis of Breast Cancer Tissue Shows ANXA2 is Specifically Upregulated in ER 
Negative Breast Cancer and Correlates with Rates of Metastasis 
Due to our accumulating evidence of Annexin A2′s importance in breast cancer progression in 
our in vitro cell models, we next investigated its expression in breast cancer patient tissue. RT-qPCR 
was used to analyze the level of ANXA2 mRNA in core biopsy tissue samples (normal = 5, cancer = 
30). Surprisingly, despite several reports in the literature that ANXA2 is upregulated in breast cancer 
[42,59,60], we observed that expression of ANXA2 is significantly down regulated (p = 0.0002, Mann 
Whitney U test) in breast cancer tissue in comparison to pathologically normal breast tissue (Figure 
5A). When ANXA2 expression levels were stratified according to nodal involvement—an indicator 
of breast cancer disease progression—we found a trend of increased ANXA2 expression in those who 
had nodal positive disease, but this was not statistically significant (p = 0.8674, Mann Whitney U test). 
Due to the sample size of this local cohort, the expression of ANXA2 according to receptor status 
could not be carried out reliably (ER+ = 24, ER- = 2, see Table S3). Thus, to add power to our 
investigation and to further interrogate the relationship between ER status and ANXA2 expression 
we then extended our study to publicly available gene expression datasets. 
The NCBI GEO database is a public functional genomics data repository through which 
anonymized gene expression and corresponding clinical attributes can be accessed and analyzed. The 
dataset GSE42568 was chosen to closely reflect our local experimental cohort as it also contained gene 
expression data from normal (n = 17) and breast cancer (n = 104) tissue from Irish patients. Fold change 
of ANXA2 expression was measured as log2 using Affymetrix microarrays and probe set 201590_x_at 
and differences between groups was measured using Student’s t-test. Analysis of this data set (Figure 
5B) also showed a significant down regulation in ANXA2 in breast tumor tissue compared to normal 
breast tissue (p < 0.0001, Mann–Whitney U). Further, by categorizing the GSE42568 cohort according 
to ER expression, we see that ANXA2 expression is significantly upregulated in those with ER 
negative breast cancer tissue (p = 0.0094, Student’s t-test), which is consistent with our cell line data. 
Reflecting the results seen in our RT-qPCR local cohort, ANXA2 appears to be slightly increased in 
those with nodal progression in GSE42568 (p = 0.1121, Student’s t-test). The expression status of other 
receptors such as progesterone receptor (PR) and HER-2 were not recorded for this dataset (Table 
S4). To further verify the relationship between Annexin A2 and ER- breast cancer tissue, we 
interrogated available quantitative proteomic data from S. Tyanova et. al. (2016) [25]. Through this 
we found, in support of our argument, that Annexin A2 expression at the level of the protein is 
significantly higher in ER- breast cancer tissue (p = 0.0185, Student’s t-test) (Figure S5). 
These trends are further evidenced by querying the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) cohort for ANXA2 expression. METABRIC is a publicly available 
database containing genomic and clinical data for over 2000 breast cancer patients [61]. As illustrated 
in Figure 5C, again, ER negative patients appear to have a higher expression of ANXA2 (p < 0.0001, 
Mann–Whitney U). When considering expression of other receptors, it can be seen that PR negative 
patients have a slight increase in ANXA2 expression overall (p = 0.0037, Mann–-Whitney U), whereas 
HER-2 positive patients have increased ANXA2 expression compared to those who do not have HER-
2 overexpression (p < 0.0001, Mann–Whitney U). The 3-gene classifier postulated by Haibe-Kains B et 
al. [62] allows for the stratification of tumor samples into four main clinical subtypes: ER+ high 
proliferation, ER+ low proliferation, TNBC (denoted as ER-/HER2- in METABRIC) and HER2+. 
Comparing ANXA2 expression between these subtypes reveals both ER positive subtypes to have a 
significantly lower expression of ANXA2 than their ER negative counterparts. (TNBC vs. ER+hi 
prolif, p < 0.0001; TNBC- vs. HER2+, p = 0.2737; TNBC vs. ER+ lo prolif, p < 0.0001; ER+ hi prolif vs. 
HER2+, p < 0.0001; ER+ hi prolif vs. ER+ lo prolif, p = 0.4909; HER2+ vs. ER+lo prolif, p < 0.0001, 
Kruskal-Wallis with Dunns adjustment). Once more, analysis of this large breast cancer cohort 
appears to link ANXA2 expression with ER negative breast cancer, encompassing both the aggressive 
triple negative and HER-2 overexpressing subtypes. In addition, those with a positive nodal status 
also have an increased expression of ANXA2 when compared to those without nodal involvement, 
regardless of receptor status (p = 0.0050, Mann–Whitney U). 
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Taking into account the specificity we see of ANXA2 overexpression in ER-negative breast 
cancer and the potential influence ANXA2 has on disease progression in terms of lymph node 
involvement, we then wanted to ascertain the effect ANXA2 expression has on prognosis for breast 
cancer patients. Gene expression and survival data sets were downloaded from KMPlot.com and 
categorized according to ER expression (derived from gene expression data) [26]. Kaplan–Meier plots 
and log-rank tests were used to compare the distant metastasis free survival (DMFS) rates of patients 
stratified according to high or low ANXA2 expression, illustrated in Figure 5D. Using a median value 
as high/low cut off for ANXA2 expression, we found that for ER positive patients (n = 1395), ANXA2 
expression had no significant effect on DMFS. Contrastingly, in patients with ER negative breast 
cancer (n = 351), high ANXA2 expression had a significant detrimental effect on DMFS, with a hazard 
ratio showing that those with high expression were almost 2 times more likely to develop distant 
metastasis (p = 0.0068, HR = 1.730). These results indicate that ANXA2 expression is correlated with 
poor clinical outcome, specifically distant metastasis for only the ER negative grouping of breast 
cancer patients. 
 
Figure 5. ANXA2 expression is associated with and is a prognostic indicator in ER negative breast 
cancer. (A) Analysis of ANXA2 expression using qRT-PCR of normal (n = 5) and breast cancer (n = 30) 
tissue samples. Analysis showed ANXA2 is significantly upregulated in normal tissue versus cancer 
tissue (p = 0.0002). Gene expression represented as fold change from normal closest to mean. 
Horizontal bars represent the mean and SD of fold change. Statistical difference between groups 
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tested using Mann Whitney U test. (B) Analysis of ANXA2 mRNA expression in GSE42568 showing 
ANXA2 is upregulated in normal tissue versus cancer tissue, (p < 0.0001), in ER- breast cancer versus 
ER+ breast cancer (p = 0.0094) and in patients with nodal positive disease (p = 0.1121). Horizontal bars 
represent the mean and SD gene expression levels. Statistical difference between groups was 
measured using Student’s t-test. (C) Analysis of ANXA2 mRNA expression of the METABRIC cohort 
showing upregulation of ANXA2 in ER negative (p < 0.0001), PR positive (p = 0.0013) HER2 positive 
(p < 0.0001) and in nodal positive (p = 0.0050) breast cancer patients. Using the 3 gene classifier (42) to 
stratify patients shows TNBC and HER2+ subtypes to have significantly higher expression of ANXA2 
than both ER+/HER2- subtypes. Statistical difference between groups was calculated using Mann–
Whitney U test. (D) Kaplan–Meier curves comparing the DMFS of patients with high ANXA2 
expression (red) versus low ANXA2 expression (black) as determined by median expression value 
cut-off. Curves were analyzed using univariate log-rank tests. Expression of ANXA2 was found to 
not have a significant effect in ER+ patients whereas it did significantly increase probability of distant 
metastasis for ER- patients (p = 0.0068). 
4. Discussion 
In this study, we utilized well-established transwell chamber assays, in combination with the 
BONCAT method and mass spectrometry to identify the nascent proteome that is synthesized when 
breast cancer cells undergo migration and invasion towards an EGF chemoattractant. This is an 
innovative method to assess the global proteomic changes that occur during these processes of cancer 
progression using an in vitro model. This experimental set-up allowed for a highly specific and 
controlled insight into the early translational events involved in the metastatic process in a model of 
aggressive ER negative breast cancer. Functional analysis of the proteins identified in this procedure 
showed that a wide range of cellular functions were regulated by the chemotactic EGF stimulation. 
Of these functions, gene ontology enrichment analysis revealed calcium ion binding to be the most 
significantly overrepresented GO term within our list. Calcium signaling has well-established links 
to processes of cancer progression such as proliferation, apoptosis and migration and invasion 
[63,64]. Furthermore, calcium flux has an intrinsic role in the breast due to lactation and the 
expression of several calcium pumps, involved in milk production, have been implicated in breast 
cancer [65]. Altered calcium homeostasis has been observed within breast cancer, however, it is 
currently unclear whether the dysregulation of calcium binding proteins like Annexin A2 are a cause 
or a consequence of this imbalance [64]. Despite this, it is known that Ca2+ level within the cell 
regulates Annexin A2′s affinity for its binding partners and cellular components such as the plasma 
membrane and the actin cytoskeleton [51,66,67]. Apart from Annexin A2, calcium binding proteins 
such as the S100 family (several of which were identified in our screen, Table S1) have been 
thoroughly investigated in the context of cancer, as reviewed by Bresnick et al. [68] and these, along 
with Annexin A2, have the potential to be utilized as prognostic or therapeutic targets in breast cancer 
[69]. As well as successfully identifying Annexin A2 as a mediator of breast cancer cell migration and 
invasion, our screen has provided an extensive list of proteins potentially involved in breast cancer 
metastasis which require further investigation (Table S1). This valuable information can guide our 
and others’ future research into deciphering the mechanics of cancer progression. 
As migration and invasion constitute integral mechanisms in the development of cancer 
metastasis, the proteins identified by our model and mass spectrometry screen potentially have a role 
in cancer progression. We thus tested the value of our experimental design by conducting a focused 
study on Annexin A2—a protein identified in both our migration and invasion experiments. Annexin 
A2 is a calcium ion regulated membrane binding protein [67] found to play a role in a wide range of 
cellular processes, from endo- and exo- cytosis to proliferation and apoptosis [51]. One of its best-
known functions is its hand in the proteolytic cascade, triggered by the activation of plasmin. The 
plasminogen activation system is vital for the tissue remodeling required for wound healing. This 
process however, has also been associated with cancer progression [70]. AnxA2 promotes the 
conversion of the inactive pre-protein plasminogen into its active version, the serine protease called 
plasmin. AnxA2 does this by binding both tissue plasminogen activator (tPA) and plasminogen thus 
bringing enzyme and substrate together spatially and significantly increasing the rate of conversion 
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[71]. This fibrinolytic process produces proteases with the ability to degrade extracellular matrix 
(ECM) proteins and further activate matrix metallo-proteases (MMPs). When dysregulated, this 
degradation ability greatly accelerates the progression of cancer by giving the tumor a greater chance 
to invade through the ECM and metastasize to other locations in the body [60]. Annexin A2 has been 
proposed as a potential biomarker and therapeutic target for aggressive and metastatic cancers 
[72,73]. A recent study by Shen et al. even postulated the use of phosphorylated Annexin A2 for the 
selective imaging of solid tumors within the clinic [74]. Studies by Sharma et al. [58] and Yeatman et 
al. [75] have actually shown that the expression of Annexin A2 is higher in metastatic cancer cell lines 
versus non-metastatic cancer cells. The recent authoritative review by Sharma discusses these studies 
and similar findings in a number of cancer types and concluded by proposing Annexin A2 to be a 
universal signature of aggressive and metastatic cancer [72]. Our approach has added to the 
consensus that Annexin A2 plays an important role in the progression of breast cancer, suggesting 
that stimulus to migrate and invade with an EGF chemoattractant actually induces the nascent 
translation of Annexin A2. 
The patterns of higher Annexin A2 expression at both a protein and gene level, as demonstrated 
using both western blotting and RT-qPCR methods (Figure 3A,C), as well as through interrogating 
independent genomic and proteomic data repositories (Figure 3B,C) suggested the importance of 
Annexin A2 expression in ER negative breast cancer. Thus, we next assessed the functional 
consequences of decreasing Annexin A2 expression using RNA interference techniques within an ER 
negative breast cancer model. Knockdown of Annexin A2 attenuated many of the traditional 
hallmarks of cancer exhibited by MDA-MB-231 cells. Cell growth and proliferation was diminished, 
adding to the evidence of Annexin A2′s role in cell division, as reported in a number of experimental 
models [76,77]. Cell migration, as measured by both wound healing assay and EGF-induced 
directional migration, was significantly diminished upon reduction of Annexin A2 expression. As 
discussed earlier, cancer cell motility and chemotactic response to factors found within the tumor 
microenvironment are pillars of metastatic progression. Annexin A2 has been implicated in cell 
motility due to its role in binding actin filaments, regulating filament polymerization, and 
cytoskeletal organization [35–37]. In addition, it has been shown to recruit Rho GTPases, cofilin and 
other motility associated effector proteins [38,39,45,78,79] This role of Annexin A2 in promoting 
breast cancer cell migration equates with results from previous research [44,80,81] but to our 
knowledge is the first instance to show the specific reaction to an EGF gradient. To further validate 
the clinically relevant role of Annexin A2 in metastasis, future investigations are needed. Studies 
using Matrigel plug assays [82] and xenograft models [83] have indicated the potential of targeting 
Annexin A2 in angiogenesis and tumor growth in vivo. However, various measurements of invasion 
such as 3-D spheroid formation and gelatin zymography, in combination with physiologically 
relevant, spontaneous metastatic mouse models (such as those used in [84]) are essential for a fully 
comprehensive insight into Annexin A2′s role in the metastatic cascade. 
A link with EGF signaling could be contributed to the interaction between Annexin A2 and the 
EGF receptor (EGFR). Our results (Figure 3B(ii)) indicate a strong correlation between the expression 
of EGFR and Annexin A2 in ER negative cell line models. However, within the literature, this 
relationship is riddled with conflicting reports with some data showing that reduction of Annexin 
A2 dampens the downstream activation of the EGFR pathway [44]; while others report that inhibition 
of Annexin A2 expression enhanced both EGF induced cell migration and downstream activation of 
JNK and Akt in mouse models [45]. Indeed, our results (Figure 3D) and others [85], show that EGF 
stimulation appears to transiently increase Annexin A2 phosphorylation at Tyr24. This 
phosphorylation is likely caused by EGFR mediated activation of Src kinase, of which Annexin A2 is 
a known substrate [44]. Current literature suggest that this phosphorylation promotes Annexin A2 
translocation to cell and exosomal surfaces where it can enact its pro-metastatic functions by bridging 
proteins together to activate ECM remodeling enzymes and even attract pro-tumorigenic 
macrophages into the TME [54,58,81,86–88]. Recent work by Y Fan et al., showed that the reduction 
in migration and invasion attributed to Annexin A2 suppression can be rescued by the exogenous 
expression of a phospho-mimic-ANXA2 but not by a phospho-null-ANXA2, highlighting the 
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importance of the phosphorylation we have observed [53]. Furthermore, a number of studies have 
linked growth factor mediated phosphorylation of Annexin A2 to the promotion of EMT in a variety 
cancer types [55–57,81]. Although the methods used for assessing EMT vary, many come to the 
consensus that Annexin A2 plays a role in triggering the mesenchymal and migratory phenotype in 
cancer cells via the transcriptional program of EMT. This agrees with our observations of Annexin 
A2 suppression diminishing the migratory capacity of breast cancer cells (Figure 4C,D) and 
potentially correlating with loss of EMT marker, E-Cadherin, in specific cases (Figure 3A). Despite 
the increase in Annexin A2 phosphorylation and the nascent translation proposed by our mass 
spectrometry identification (Figure 3D), the level of total Annexin A2 within the cell remains constant 
when measured by western blot. This is similar to results seen by Maji et al. in which exosomal 
Annexin A2 was seen to increase in a progressively metastatic breast cancer cell line model, despite 
seeing no change when the whole cell lysate is analyzed [87]. This could suggest that the total cellular 
pool outweighs the newly synthesized pool of Annexin A2 that is translated upon directional EGF 
stimulation, thus masking any potential increase in protein levels. This is supported by reports of 
Annexin A2 having a long half-life (40–50 h) [89–91] and by our own findings that suggest that it is 
only 72 h post transfection with siRNA against ANXA2 that we see the knockdown and maintenance 
of its knockdown beyond 35% (data not shown). Further examination is ongoing to ascertain whether 
Annexin A2 is newly synthesized during this process to replace the protein lost to cell surface 
translocation. Exosomal or secreted Annexin A2 has been reported to promote breast cancer 
metastasis and angiogenesis in a number of studies [58,82,87] and has even been proposed as a serum 
based biomarker for breast cancer detection [82,92]. Taken together, this suggests that Annexin A2 is 
involved in processes that promote breast cancer disease progression and this could be particularly 
true for tumors driven by EGFR overexpression. This is further compacted by our findings of a 
significant correlation between Annexin A2 and EGFR expression and by the observation that breast 
cancers found to have EGFR overexpression are more commonly ER negative than ER positive [93]. 
Having established the importance of Annexin A2 expression in maintaining proliferation, 
wound healing, and migration within our in vitro model (Figure 3), we next moved to investigate its 
expression in patient tissue. Interestingly, we found that when unstratified breast cancer samples 
were compared to normal breast tissue, Annexin A2 expression was significantly lower in the cancer 
tissue. This finding was validated in the larger GSE4825 cohort. This is in contrast to 
immunohistochemical analysis by Sharma et al. [58] which showed Annexin A2 to be undetectable 
in normal breast epithelia but strongly and consistently expressed in invasive breast cancer tissue. 
This discrepancy could be explained by a differential level of translational control between mRNA to 
protein. However, this requires further investigation as our result poses a challenge to the current 
general consensus that Annexin A2 is upregulated in breast cancer compared to pathologically 
normal tissue [42,59,60]. 
The stratification of breast cancer patients according to their ER expression status (GSE42568, 
METABRIC and S. Tyanova, et. al. (2016) cohorts) revealed that the trend seen in cell lines also applies 
to human breast cancer tissue samples. ER negative breast cancer encompasses both the triple 
negative and HER-2 overexpressing subtypes [49]. These are often more aggressive and have fewer 
treatment strategies in comparison with the more common ER positive breast cancers. Women 
diagnosed with ER negative tumors are usually diagnosed at an earlier age and experience a higher 
mortality rate [94]. With the exception of trastuzumab’s unmatched beneficial effect for HER-2 
positive patients [95], traditionally, toxic and unspecific chemotherapy is used to treat ER negative 
tumors. In addition, a caveat to the success of trastuzumab for HER-2 positive breast cancer is that a 
large majority of those treated develop resistance over time [96]. This highlights the need for targeted 
therapies which can mimic the wide reaching success of anti-estrogens such as tamoxifen for ER 
positive cancers [97]. The large sample size of the METABRIC analysis also revealed Annexin A2 to 
be upregulated in HER2 positive breast cancer, contradicting what has been previously published 
[44] and suggesting the value of investigating Annexin A2 in breast cancer is not limited to the triple 
negative subtypes. The potential of Annexin A2 as a therapeutic target or marker of aggressiveness 
in ER negative breast cancer is further solidified by its links to disease progression and metastasis. 
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Analysis of our local tissue cohort (RT-qPCR), GSE42568, and the METABRIC (Affymetrix) cohort all 
show that Annexin A2 expression is higher in patients with lymph node involvement (Figure 5A-C). 
Due to the lymphatic drainage of the breast tissue, the lymph nodes are often the first location of 
metastatic spread. Presence of metastasized tumor cells in the axillary lymph nodes is one of the 
strongest prognostic indicators in breast cancer [98] and as a result, lymph node status is a parameter 
used to stage the disease [99]. The trend of higher ANXA2 expression in patients with lymph node 
involvement in our local cohort and the larger GSE42568, is not statistically significant, however, this 
could be attributed to the fact that only a small proportion of patients in these cohorts are ER negative 
(Table S3 and Table S4), thus masking the possible effect of ANXA2 expression on disease 
progression. Annexin A2 is again associated with metastatic progression of disease when we show 
that risk of distant metastasis is significantly higher in ER negative breast cancer patients with high 
expression of ANXA2. This statistically significant result does not hold true for ER positive patients, 
providing evidence that the potential of targeting Annexin A2 holds promise for the more aggressive 
and harder to treat ER negative breast cancers. 
5. Conclusions 
Collectively, we have developed a novel approach to assess the changes that occur in the nascent 
proteome when cancer cells undergo stimulation to carry out the pro-metastatic functions of invasion 
and migration. We have proven the validity and usefulness of this approach by demonstrating how 
Annexin A2, one of the elucidated proteins, plays a pivotal role in maintaining the malignant 
phenotype of estrogen receptor negative breast cancer. The variety of experimental techniques and 
independent transcriptomic and proteomic datasets encompassing both cell line models and patient 
tissue in this study provides an emphatic argument that Annexin A2 plays a key role in ER negative 
breast cancer. Our work has used innovative models to add substantial weight to the findings by 
others, linking Annexin A2 to breast cancer. This study provides novel insight into the potential 
mechanisms of metastasis in ER negative breast cancer. Further validation is needed to build upon 
this study and truly assess the viability of targeting Annexin A2 to prevent cancer metastasis in vivo. 
Ultimately, this knowledge suggests that targeting Annexin A2 merits investigation as a novel 
therapeutic strategy in treating the pharmacologically challenging ER negative subtype, and this may 
help prevent breast cancer progression to the later metastatic stages of disease. 
Supplementary Materials: The following are available online at www.mdpi.com/2073-4409/9/7/1582/s1. Figure 
S1: (A) Score and sequence coverage of Annexin A2 from mass spectrometry and MASCOT server results (B) 
representative mass spectrum of AnxA2 peptide Figure S2: Proteomic expression data for CCLE cell lines from 
Nusinow, D. P. et al. (2020) Figure S3: Publicly available Affymetrix gene expression data for human breast 
cancer cell lines. Figure S4: Additional functional assays with second siRNA clone on MDA-MB-231 cells. Figure 
S5: Proteomic expression data for breast cancer tissue samples from S. Tyanova, et al. (2016). Figure S6, S7, and 
S8: full, uncropped images of western blots in manuscript. Table S1: List of newly synthesised proteins identified 
in 2D migration experiment. Table S2: List of newly synthesised proteins identified in 3D invasion experiment. 
Table S3: Sequences of the small interfering RNA used for ANXA2 knockdown. Table S4: Clinical information 
of local breast cancer cohort (n = 30) Table S5. Clinical information of GSE42568 breast cancer cohort (n = 104).  
Author Contributions: A.M. and P.K. designed the experiments and wrote the manuscript. A.M. performed the 
experiments and interpreted results. B.M., J.N. & K.M.G. assisted with experimental design and collection, 
interpretation and visualization of data. B.M., J.N., A.J.L. & K.M.G. also performed manuscript editing. MM, 
A.M., A.L. and S.T. collected informed consent, tissue, and pathological data from patients. P.K., K.M.G. and 
A.J.L. conceived and supervised the study. All authors read, and approved the final manuscript. 
Funding: This work was supported by grants received from the Irish Research Council, Grant GOIPG/2016/1547 
(to AM), Science Foundation Ireland, Grant 13/CDA/2228 (to PK) and the Mid-Western Cancer Foundation (to 
PK). 
Acknowledgments: We are grateful to our colleagues in the Laboratory of Cellular and Molecular Biology for 
helpful discussions and critical review. Additionally, we are grateful to all patients and their families from 
University Hospital Limerick who generously donated tissue to the Breast Biobank. 
Conflicts of Interest: The authors declare no conflict of interest. 
Cells 2020, 9, 1582 20 of 24 
 
References 
1. Balkwill, F.R.; Capasso, M.; Hagemann, T. The tumor microenvironment at a glance. J. Cell Sci 2012, 125, 
5591–5596, doi:10.1242/jcs.116392. 
2. Sahai, E. Illuminating the metastatic process. Nat. Rev. Cancer 2007, 7, 737–749, doi:10.1038/nrc2229. 
3. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. 
Nat. Rev. Cancer 2002, 2, 563–572, doi:10.1038/nrc865. 
4. Stuelten, C.H.; Parent, C.A.; Montell, D.J. Cell motility in cancer invasion and metastasis: Insights from 
simple model organisms. Nat. Rev. Cancer 2018, 18, 296–312, doi:10.1038/nrc.2018.15. 
5. Welch, D.R.; Hurst, D.R. Defining the Hallmarks of Metastasis. Cancer Res. 2019, 79, 3011–3027, 
doi:10.1158/0008-5472.CAN-19-0458. 
6. Albini, A.; Benelli, R.; Noonan, D.M.; Brigati, C. The “chemoinvasion assay”: A tool to study tumor and 
endothelial cell invasion of basement membranes. Int J. Dev. Biol 2004, 48, 563–571, 
doi:10.1387/ijdb.041822aa. 
7. Harbeck, N.; Penault-Llorca, F.; Cortes, J.; Gnant, M.; Houssami, N.; Poortmans, P.; Ruddy, K.; Tsang, J.; 
Cardoso, F. Breast cancer. Nat. Rev. Dis Primers 2019, 5, 66, doi:10.1038/s41572-019-0111-2. 
8. Kennecke, H.; Yerushalmi, R.; Woods, R.; Cheang, M.C.; Voduc, D.; Speers, C.H.; Nielsen, T.O.; Gelmon, 
K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol 2010, 28, 3271–3277, 
doi:10.1200/JCO.2009.25.9820. 
9. Dieterich, D.C.; Link, A.J.; Graumann, J.; Tirrell, D.A.; Schuman, E.M. Selective identification of newly 
synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging 
(BONCAT). Proc. Natl Acad Sci Usa 2006, 103, 9482–9487, doi:10.1073/pnas.0601637103. 
10. Schwanhausser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global 
quantification of mammalian gene expression control. Nature 2011, 473, 337–342, doi:10.1038/nature10098. 
11. Geiger, T.; Madden, S.F.; Gallagher, W.M.; Cox, J.; Mann, M. Proteomic portrait of human breast cancer 
progression identifies novel prognostic markers. Cancer Res. 2012, 72, 2428–2439, doi:10.1158/0008-
5472.CAN-11-3711. 
12. Yanovich, G.; Agmon, H.; Harel, M.; Sonnenblick, A.; Peretz, T.; Geiger, T. Clinical Proteomics of Breast 
Cancer Reveals a Novel Layer of Breast Cancer Classification. Cancer Res. 2018, 78, 6001–6010, 
doi:10.1158/0008-5472.CAN-18-1079. 
13. Al-Wajeeh, A.S.; Salhimi, S.M.; Al-Mansoub, M.A.; Khalid, I.A.; Harvey, T.M.; Latiff, A.; Ismail, M.N. 
Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance 
liquid chromatography tandem mass spectrometer. PLoS ONE 2020, 15, e0227404, 
doi:10.1371/journal.pone.0227404. 
14. Chakraborty, S.; Hosen, M.I.; Ahmed, M.; Shekhar, H.U. Onco-Multi-OMICS Approach: A New Frontier in 
Cancer Research. Biomed. Res. Int 2018, 2018, 9836256, doi:10.1155/2018/9836256. 
15. Mi, H.; Muruganujan, A.; Ebert, D.; Huang, X.; Thomas, P.D. PANTHER version 14: More genomes, a new 
PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019, 47, D419-
D426, doi:10.1093/nar/gky1038. 
16. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, 
N.T.; Morris, J.H.; Bork, P., et al. STRING v11: Protein-protein association networks with increased 
coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 
47, D607-D613, doi:10.1093/nar/gky1131. 
17. Doncheva, N.T.; Morris, J.H.; Gorodkin, J.; Jensen, L.J. Cytoscape StringApp: Network Analysis and 
Visualization of Proteomics Data. J. Proteome Res. 2019, 18, 623–632, doi:10.1021/acs.jproteome.8b00702. 
18. Dowling, C.M.; Walsh, D.; Coffey, J.C.; Kiely, P.A. The importance of selecting the appropriate reference 
genes for quantitative real time PCR as illustrated using colon cancer cells and tissue. F1000Res 2016, 5, 99, 
doi:10.12688/f1000research.7656.2. 
19. Nusinow, D.P.; Szpyt, J.; Ghandi, M.; Rose, C.M.; McDonald, E.R., 3rd; Kalocsay, M.; Jane-Valbuena, J.; 
Gelfand, E.; Schweppe, D.K.; Jedrychowski, M., et al. Quantitative Proteomics of the Cancer Cell Line 
Encyclopedia. Cell 2020, 180, 387–402 e316, doi:10.1016/j.cell.2019.12.023. 
20. Nusinow, D.P.; Gygi, S.P. A Guide to the Quantitative Proteomic Profiles of the Cancer Cell Line 
Encyclopedia. bioRxiv 2020, doi:10.1101/2020.02.03.932384. 
Cells 2020, 9, 1582 21 of 24 
 
21. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehar, J.; 
Kryukov, G.V.; Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature 2012, 483, 603–607, doi:10.1038/nature11003. 
22. Smith, S.E.; Mellor, P.; Ward, A.K.; Kendall, S.; McDonald, M.; Vizeacoumar, F.S.; Vizeacoumar, F.J.; 
Napper, S.; Anderson, D.H. Molecular characterization of breast cancer cell lines through multiple omic 
approaches. Breast Cancer Res. 2017, 19, 65, doi:10.1186/s13058-017-0855-0. 
23. Dai, X.; Cheng, H.; Bai, Z.; Li, J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor 
Subtyping. J. Cancer 2017, 8, 3131–3141, doi:10.7150/jca.18457. 
24. Clarke, C.; Madden, S.F.; Doolan, P.; Aherne, S.T.; Joyce, H.; O’Driscoll, L.; Gallagher, W.M.; Hennessy, 
B.T.; Moriarty, M.; Crown, J., et al. Correlating transcriptional networks to breast cancer survival: A large-
scale coexpression analysis. Carcinogenesis 2013, 34, 2300–2308, doi:10.1093/carcin/bgt208. 
25. Tyanova, S.; Albrechtsen, R.; Kronqvist, P.; Cox, J.; Mann, M.; Geiger, T. Proteomic maps of breast cancer 
subtypes. Nat. Commun 2016, 7, 10259, doi:10.1038/ncomms10259. 
26. Gyorffy, B.; Lanczky, A.; Eklund, A.C.; Denkert, C.; Budczies, J.; Li, Q.; Szallasi, Z. An online survival 
analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data 
of 1,809 patients. Breast Cancer Res. Treat. 2010, 123, 725–731, doi:10.1007/s10549-009-0674-9. 
27. Price, J.T.; Tiganis, T.; Agarwal, A.; Djakiew, D.; Thompson, E.W. Epidermal growth factor promotes MDA-
MB-231 breast cancer cell migration through a phosphatidylinositol 3’-kinase and phospholipase C-
dependent mechanism. Cancer Res. 1999, 59, 5475–5478. 
28. Wang, S.J.; Saadi, W.; Lin, F.; Minh-Canh Nguyen, C.; Li Jeon, N. Differential effects of EGF gradient 
profiles on MDA-MB-231 breast cancer cell chemotaxis. Exp. Cell Res. 2004, 300, 180–189, 
doi:10.1016/j.yexcr.2004.06.030. 
29. Lu, Z.; Jiang, G.; Blume-Jensen, P.; Hunter, T. Epidermal growth factor-induced tumor cell invasion and 
metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol. Cell. Biol. 
2001, 21, 4016–4031, doi:10.1128/MCB.21.12.4016-4031.2001. 
30. Biswenger, V.; Baumann, N.; Jurschick, J.; Hackl, M.; Battle, C.; Schwarz, J.; Horn, E.; Zantl, R. 
Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly 
sensitive assay system. PLoS ONE 2018, 13, e0203040, doi:10.1371/journal.pone.0203040. 
31. Sayers, E.W.; Agarwala, R.; Bolton, E.E.; Brister, J.R.; Canese, K.; Clark, K.; Connor, R.; Fiorini, N.; Funk, K.; 
Hefferon, T., et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids 
Res. 2019, 47, D23-D28, doi:10.1093/nar/gky1069. 
32. Gerke, V.; Moss, S.E. Annexins: From structure to function. Physiol Rev. 2002, 82, 331–371, 
doi:10.1152/physrev.00030.2001. 
33. Boye, T.L.; Nylandsted, J. Annexins in plasma membrane repair. Biol Chem 2016, 397, 961–969, 
doi:10.1515/hsz-2016-0171. 
34. Hajjar, K.A. The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity. Trans. Am. Clin. 
Clim. Assoc. 2015, 126, 144–155. 
35. Grieve, A.G.; Moss, S.E.; Hayes, M.J. Annexin A2 at the interface of actin and membrane dynamics: A focus 
on its roles in endocytosis and cell polarization. Int J. Cell Biol 2012, 2012, 852430, doi:10.1155/2012/852430. 
36. Xiao, L.; Jin, H.; Duan, W.; Hou, Y. Roles of N-terminal Annexin A2 phosphorylation sites and miR-206 in 
colonic adenocarcinoma. Life Sci 2020, 253, 117740, doi:10.1016/j.lfs.2020.117740. 
37. Morel, E.; Parton, R.G.; Gruenberg, J. Annexin A2-dependent polymerization of actin mediates endosome 
biogenesis. Dev. Cell 2009, 16, 445–457, doi:10.1016/j.devcel.2009.01.007. 
38. Rescher, U.; Ludwig, C.; Konietzko, V.; Kharitonenkov, A.; Gerke, V. Tyrosine phosphorylation of annexin 
A2 regulates Rho-mediated actin rearrangement and cell adhesion. J. Cell Sci 2008, 121, 2177–2185, 
doi:10.1242/jcs.028415. 
39. de Graauw, M.; Tijdens, I.; Smeets, M.B.; Hensbergen, P.J.; Deelder, A.M.; van de Water, B. Annexin A2 
phosphorylation mediates cell scattering and branching morphogenesis via cofilin Activation. Mol. Cell. 
Biol. 2008, 28, 1029–1040, doi:10.1128/MCB.01247-07. 
40. Bunnell, T.M.; Burbach, B.J.; Shimizu, Y.; Ervasti, J.M. beta-Actin specifically controls cell growth, 
migration, and the G-actin pool. Mol. Biol Cell 2011, 22, 4047–4058, doi:10.1091/mbc.E11-06-0582. 
41. Grewal, T.; Wason, S.J.; Enrich, C.; Rentero, C. Annexins—insights from knockout mice. Biol Chem 2016, 
397, 1031–1053, doi:10.1515/hsz-2016-0168. 
Cells 2020, 9, 1582 22 of 24 
 
42. Christensen, M.V.; Hogdall, C.K.; Jochumsen, K.M.; Hogdall, E.V.S. Annexin A2 and cancer: A systematic 
review. Int J. Oncol 2018, 52, 5–18, doi:10.3892/ijo.2017.4197. 
43. Zhao, W.Q.; Chen, G.H.; Chen, H.; Pascale, A.; Ravindranath, L.; Quon, M.J.; Alkon, D.L. Secretion of 
Annexin II via activation of insulin receptor and insulin-like growth factor receptor. J. Biol Chem 2003, 278, 
4205–4215, doi:10.1074/jbc.M210545200. 
44. Shetty, P.K.; Thamake, S.I.; Biswas, S.; Johansson, S.L.; Vishwanatha, J.K. Reciprocal regulation of annexin 
A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. PLoS ONE 2012, 7, e44299, 
doi:10.1371/journal.pone.0044299. 
45. de Graauw, M.; Cao, L.; Winkel, L.; van Miltenburg, M.H.; le Devedec, S.E.; Klop, M.; Yan, K.; Pont, C.; 
Rogkoti, V.M.; Tijsma, A., et al. Annexin A2 depletion delays EGFR endocytic trafficking via cofilin 
activation and enhances EGFR signaling and metastasis formation. Oncogene 2014, 33, 2610–2619, 
doi:10.1038/onc.2013.219. 
46. Frohlich, M.; Motte, P.; Galvin, K.; Takahashi, H.; Wands, J.; Ozturk, M. Enhanced expression of the protein 
kinase substrate p36 in human hepatocellular carcinoma. Mol. Cell. Biol. 1990, 10, 3216–3223, 
doi:10.1128/mcb.10.6.3216. 
47. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674, 
doi:10.1016/j.cell.2011.02.013. 
48. Fendt, S.M. Metabolic vulnerabilities of metastasizing cancer cells. BMC Biol 2019, 17, 54, 
doi:10.1186/s12915-019-0672-2. 
49. Sorlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, 
M.; Jeffrey, S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proc. Natl Acad Sci U S A 2001, 98, 10869–10874, doi:10.1073/pnas.191367098. 
50. Grindheim, A.K.; Saraste, J.; Vedeler, A. Protein phosphorylation and its role in the regulation of Annexin 
A2 function. Biochim Biophys Acta Gen. Subj 2017, 1861, 2515–2529, doi:10.1016/j.bbagen.2017.08.024. 
51. Bharadwaj, A.; Bydoun, M.; Holloway, R.; Waisman, D. Annexin A2 heterotetramer: Structure and 
function. Int J. Mol. Sci 2013, 14, 6259–6305, doi:10.3390/ijms14036259. 
52. Lokman, N.A.; Ween, M.P.; Oehler, M.K.; Ricciardelli, C. The role of annexin A2 in tumorigenesis and 
cancer progression. Cancer Microenviron 2011, 4, 199–208, doi:10.1007/s12307-011-0064-9. 
53. Fan, Y.; Si, W.; Ji, W.; Wang, Z.; Gao, Z.; Tian, R.; Song, W.; Zhang, H.; Niu, R.; Zhang, F. Rack1 mediates 
tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast 
cancer cells. Breast Cancer Res. 2019, 21, 66, doi:10.1186/s13058-019-1147-7. 
54. Zheng, L.; Foley, K.; Huang, L.; Leubner, A.; Mo, G.; Olino, K.; Edil, B.H.; Mizuma, M.; Sharma, R.; Le, D.T., 
et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for 
invasion and metastases of pancreatic cancer. PLoS ONE 2011, 6, e19390, doi:10.1371/journal.pone.0019390. 
55. Cui, L.; Song, J.; Wu, L.; Cheng, L.; Chen, A.; Wang, Y.; Huang, Y.; Huang, L. Role of Annexin A2 in the 
EGF-induced epithelial-mesenchymal transition in human CaSki cells. Oncol Lett 2017, 13, 377–383, 
doi:10.3892/ol.2016.5406. 
56. Rocha, M.R.; Barcellos-de-Souza, P.; Sousa-Squiavinato, A.C.M.; Fernandes, P.V.; de Oliveira, I.M.; Boroni, 
M.; Morgado-Diaz, J.A. Annexin A2 overexpression associates with colorectal cancer invasiveness and 
TGF-ss induced epithelial mesenchymal transition via Src/ANXA2/STAT3. Sci. Rep. 2018, 8, 11285, 
doi:10.1038/s41598-018-29703-0. 
57. Wu, M.; Sun, Y.; Xu, F.; Liang, Y.; Liu, H.; Yi, Y. Annexin A2 Silencing Inhibits Proliferation and Epithelial-
to-mesenchymal Transition through p53-Dependent Pathway in NSCLCs. J. Cancer 2019, 10, 1077–1085, 
doi:10.7150/jca.29440. 
58. Sharma, M.R.; Koltowski, L.; Ownbey, R.T.; Tuszynski, G.P.; Sharma, M.C. Angiogenesis-associated 
protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor 
invasion and progression. Exp. Mol. Pathol 2006, 81, 146–156, doi:10.1016/j.yexmp.2006.03.003. 
59. Wang, C.Y.; Lin, C.F. Annexin A2: Its molecular regulation and cellular expression in cancer development. 
Dis Markers 2014, 2014, 308976, doi:10.1155/2014/308976. 
60. Xu, X.H.; Pan, W.; Kang, L.H.; Feng, H.; Song, Y.Q. Association of annexin A2 with cancer development 
(Review). Oncol Rep. 2015, 33, 2121–2128, doi:10.3892/or.2015.3837. 
61. Pereira, B.; Chin, S.F.; Rueda, O.M.; Vollan, H.K.; Provenzano, E.; Bardwell, H.A.; Pugh, M.; Jones, L.; 
Russell, R.; Sammut, S.J., et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic 
and transcriptomic landscapes. Nat. Commun 2016, 7, 11479, doi:10.1038/ncomms11479. 
Cells 2020, 9, 1582 23 of 24 
 
62. Haibe-Kains, B.; Desmedt, C.; Loi, S.; Culhane, A.C.; Bontempi, G.; Quackenbush, J.; Sotiriou, C. A three-
gene model to robustly identify breast cancer molecular subtypes. J. Natl Cancer Inst. 2012, 104, 311–325, 
doi:10.1093/jnci/djr545. 
63. Prevarskaya, N.; Skryma, R.; Shuba, Y. Calcium in tumour metastasis: New roles for known actors. Nat. 
Rev. Cancer 2011, 11, 609–618, doi:10.1038/nrc3105. 
64. Azimi, I.; Roberts-Thomson, S.J.; Monteith, G.R. Calcium influx pathways in breast cancer: Opportunities 
for pharmacological intervention. Br. J. Pharm. 2014, 171, 945–960, doi:10.1111/bph.12486. 
65. VanHouten, J.; Sullivan, C.; Bazinet, C.; Ryoo, T.; Camp, R.; Rimm, D.L.; Chung, G.; Wysolmerski, J. PMCA2 
regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc. Natl 
Acad Sci U S A 2010, 107, 11405–11410, doi:10.1073/pnas.0911186107. 
66. Ikebuchi, N.W.; Waisman, D.M. Calcium-dependent regulation of actin filament bundling by lipocortin-
85. J. Biol Chem 1990, 265, 3392–3400. 
67. Grill, D.; Matos, A.L.L.; de Vries, W.C.; Kudruk, S.; Heflik, M.; Dorner, W.; Mootz, H.D.; Jan Ravoo, B.; 
Galla, H.J.; Gerke, V. Bridging of membrane surfaces by annexin A2. Sci. Rep. 2018, 8, 14662, 
doi:10.1038/s41598-018-33044-3. 
68. Bresnick, A.R.; Weber, D.J.; Zimmer, D.B. S100 proteins in cancer. Nat. Rev. Cancer 2015, 15, 96–109, 
doi:10.1038/nrc3893. 
69. Cancemi, P.; Buttacavoli, M.; Di Cara, G.; Albanese, N.N.; Bivona, S.; Pucci-Minafra, I.; Feo, S. A multiomics 
analysis of S100 protein family in breast cancer. Oncotarget 2018, 9, 29064–29081, 
doi:10.18632/oncotarget.25561. 
70. Ranson, M.; Andronicos, N.M. Plasminogen binding and cancer: Promises and pitfalls. Front. Biosci 2003, 
8, s294-304, doi:10.2741/1044. 
71. Hajjar, K.A.; Krishnan, S. Annexin II: A mediator of the plasmin/plasminogen activator system. Trends 
Cardiovasc Med. 1999, 9, 128–138, doi:10.1016/s1050-1738(99)00020-1. 
72. Sharma, M.C. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for 
aggressive cancers. Int J. Cancer 2019, 144, 2074–2081, doi:10.1002/ijc.31817. 
73. Jaiswal, J.K.; Nylandsted, J. S100 and annexin proteins identify cell membrane damage as the Achilles heel 
of metastatic cancer cells. Cell Cycle 2015, 14, 502–509, doi:10.1080/15384101.2014.995495. 
74. Shen, D.; Xu, B.; Liang, K.; Tang, R.; Sudlow, G.P.; Egbulefu, C.; Guo, K.; Som, A.; Gilson, R.; Maji, D., et al. 
Selective imaging of solid tumours via the calcium-dependent high-affinity binding of a cyclic octapeptide 
to phosphorylated Annexin A2. Nat. Biomed. Eng. 2020, 4, 298–313, doi:10.1038/s41551-020-0528-7. 
75. Yeatman, T.J.; Updyke, T.V.; Kaetzel, M.A.; Dedman, J.R.; Nicolson, G.L. Expression of annexins on the 
surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin. Exp. Metastasis 1993, 11, 37–
44, doi:10.1007/bf00880064. 
76. Benaud, C.; Le Dez, G.; Mironov, S.; Galli, F.; Reboutier, D.; Prigent, C. Annexin A2 is required for the early 
steps of cytokinesis. EMBO Rep. 2015, 16, 481–489, doi:10.15252/embr.201440015. 
77. Vishwanatha, J.K.; Kumble, S. Involvement of annexin II in DNA replication: Evidence from cell-free 
extracts of Xenopus eggs. J. Cell Sci 1993, 105 ( Pt. 2), 533-540. 
78. Yang, S.F.; Hsu, H.L.; Chao, T.K.; Hsiao, C.J.; Lin, Y.F.; Cheng, C.W. Annexin A2 in renal cell carcinoma: 
Expression, function, and prognostic significance. Urol Oncol 2015, 33, 22 e11-22 e21, 
doi:10.1016/j.urolonc.2014.08.015. 
79. Zhao, P.; Zhang, W.; Wang, S.J.; Yu, X.L.; Tang, J.; Huang, W.; Li, Y.; Cui, H.Y.; Guo, Y.S.; Tavernier, J., et 
al. HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling 
pathways in hepatocellular carcinoma cells. Hepatology 2011, 54, 2012–2024, doi:10.1002/hep.24592. 
80. Sharma, M.; Ownbey, R.T.; Sharma, M.C. Breast cancer cell surface annexin II induces cell migration and 
neoangiogenesis via tPA dependent plasmin generation. Exp. Mol. Pathol 2010, 88, 278–286, 
doi:10.1016/j.yexmp.2010.01.001. 
81. Wang, T.; Yuan, J.; Zhang, J.; Tian, R.; Ji, W.; Zhou, Y.; Yang, Y.; Song, W.; Zhang, F.; Niu, R. Anxa2 binds 
to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. Oncotarget 2015, 6, 
30975–30992, doi:10.18632/oncotarget.5199. 
82. Chaudhary, P.; Gibbs, L.D.; Maji, S.; Lewis, C.M.; Suzuki, S.; Vishwanatha, J.K. Serum exosomal-annexin 
A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast 
Cancer Res. 2020, 22, 11, doi:10.1186/s13058-020-1251-8. 
Cells 2020, 9, 1582 24 of 24 
 
83. Sharma, M.C.; Tuszynski, G.P.; Blackman, M.R.; Sharma, M. Long-term efficacy and downstream 
mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of 
aggressive human breast cancer. Cancer Lett 2016, 373, 27–35, doi:10.1016/j.canlet.2016.01.013. 
84. Kijewska, M.; Viski, C.; Turrell, F.; Fitzpatrick, A.; van Weverwijk, A.; Gao, Q.; Iravani, M.; Isacke, C.M. 
Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer 
colonisation in the brain. Breast Cancer Res. 2019, 21, 4, doi:10.1186/s13058-018-1093-9. 
85. Sawyer, S.T.; Cohen, S. Epidermal growth factor stimulates the phosphorylation of the calcium-dependent 
35,000-dalton substrate in intact A-431 cells. J. Biol Chem 1985, 260, 8233–8236. 
86. Valapala, M.; Maji, S.; Borejdo, J.; Vishwanatha, J.K. Cell surface translocation of annexin A2 facilitates 
glutamate-induced extracellular proteolysis. J. Biol Chem 2014, 289, 15915–15926, 
doi:10.1074/jbc.M113.511550. 
87. Maji, S.; Chaudhary, P.; Akopova, I.; Nguyen, P.M.; Hare, R.J.; Gryczynski, I.; Vishwanatha, J.K. Exosomal 
Annexin II Promotes Angiogenesis and Breast Cancer Metastasis. Mol. Cancer Res. 2017, 15, 93–105, 
doi:10.1158/1541-7786.MCR-16-0163. 
88. Yuan, J.; Yang, Y.; Gao, Z.; Wang, Z.; Ji, W.; Song, W.; Zhang, F.; Niu, R. Tyr23 phosphorylation of Anxa2 
enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer 
Res. Treat. 2017, 164, 327–340, doi:10.1007/s10549-017-4271-z. 
89. Rescher, U.; Gerke, V. Annexins--unique membrane binding proteins with diverse functions. J. Cell Sci 2004, 
117, 2631–2639, doi:10.1242/jcs.01245. 
90. Cuervo, A.M.; Gomes, A.V.; Barnes, J.A.; Dice, J.F. Selective degradation of annexins by chaperone-
mediated autophagy. J. Biol Chem 2000, 275, 33329–33335, doi:10.1074/jbc.M005655200. 
91. Aukrust, I.; Rosenberg, L.A.; Ankerud, M.M.; Bertelsen, V.; Hollas, H.; Saraste, J.; Grindheim, A.K.; Vedeler, 
A. Post-translational modifications of Annexin A2 are linked to its association with perinuclear 
nonpolysomal mRNP complexes. FEBS Open Bio 2017, 7, 160–173, doi:10.1002/2211-5463.12173. 
92. Jeon, Y.R.; Kim, S.Y.; Lee, E.J.; Kim, Y.N.; Noh, D.Y.; Park, S.Y.; Moon, A. Identification of annexin II as a 
novel secretory biomarker for breast cancer. Proteomics 2013, 13, 3145–3156, doi:10.1002/pmic.201300127. 
93. Rimawi, M.F.; Shetty, P.B.; Weiss, H.L.; Schiff, R.; Osborne, C.K.; Chamness, G.C.; Elledge, R.M. Epidermal 
growth factor receptor expression in breast cancer association with biologic phenotype and clinical 
outcomes. Cancer 2010, 116, 1234–1242, doi:10.1002/cncr.24816. 
94. Putti, T.C.; El-Rehim, D.M.; Rakha, E.A.; Paish, C.E.; Lee, A.H.; Pinder, S.E.; Ellis, I.O. Estrogen receptor-
negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod. Pathol 2005, 
18, 26–35, doi:10.1038/modpathol.3800255. 
95. Pinto, A.C.; Ades, F.; de Azambuja, E.; Piccart-Gebhart, M. Trastuzumab for patients with HER2 positive 
breast cancer: Delivery, duration and combination therapies. Breast 2013, 22 Suppl 2, S152-155, 
doi:10.1016/j.breast.2013.07.029. 
96. Derakhshani, A.; Rezaei, Z.; Safarpour, H.; Sabri, M.; Mir, A.; Sanati, M.A.; Vahidian, F.; Gholamiyan 
Moghadam, A.; Aghadoukht, A.; Hajiasgharzadeh, K., et al. Overcoming trastuzumab resistance in HER2-
positive breast cancer using combination therapy. J. Cell Physiol 2020, 235, 3142–3156, doi:10.1002/jcp.29216. 
97. Speers, C.; Tsimelzon, A.; Sexton, K.; Herrick, A.M.; Gutierrez, C.; Culhane, A.; Quackenbush, J.; 
Hilsenbeck, S.; Chang, J.; Brown, P. Identification of novel kinase targets for the treatment of estrogen 
receptor-negative breast cancer. Clin. Cancer Res. 2009, 15, 6327–6340, doi:10.1158/1078-0432.CCR-09-1107. 
98. Verheuvel, N.C.; Ooms, H.W.; Tjan-Heijnen, V.C.; Roumen, R.M.; Voogd, A.C. Predictors for extensive 
nodal involvement in breast cancer patients with axillary lymph node metastases. Breast 2016, 27, 175–181, 
doi:10.1016/j.breast.2016.02.006. 
99. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, 
D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build 
a bridge from a population-based to a more “personalized” approach to cancer staging. Ca Cancer J. Clin. 
2017, 67, 93–99, doi:10.3322/caac.21388. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
